Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Why Moderna (MRNA) Stock Is Trading Up Today

MRNA Cover Image

What Happened?

Shares of biotechnology company Moderna (NASDAQ: MRNA) jumped 4% in the morning session after the company announced positive preliminary data for its updated 2025-2026 COVID-19 vaccine, Spikevax®. 

The new formula, which targets the LP.8.1 variant, generated a strong immune response in a Phase 4 clinical trial, showing an 8-fold increase in neutralizing antibodies in high-risk individuals and adults over 65. Moderna reported that the vaccine's safety profile remains consistent with previous studies, with no new concerns identified. The positive clinical update suggests continued demand for the company's key product. Further bolstering investor confidence, UBS reiterated its 'Buy' rating and a $70 price target on the stock.

After the initial pop the shares cooled down to $24.74, up 3.6% from previous close.

Is now the time to buy Moderna? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Moderna’s shares are extremely volatile and have had 50 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 4 days ago when the stock dropped 7.8% as reports revealed Trump administration health officials plan to link COVID-19 vaccines to the deaths of around two dozen children. 

The news, first reported by The Washington Post, sent shares of other major vaccine makers like Pfizer and BioNTech tumbling as well. According to the reports, the officials' findings are based on data from the Vaccine Adverse Event Reporting System (VAERS), a federal database that collects unfiltered and unverified reports of possible side effects from the public. The potential for a government presentation linking the vaccines to adverse outcomes has created significant investor concern. 

Adding to the uncertainty, officials are also reportedly considering new restrictions on which segments of the population should be eligible for the shots. In response, Moderna issued a statement noting that regulators in over 90 countries have not identified any new or undisclosed safety concerns regarding its vaccine in children.

Moderna is down 41.1% since the beginning of the year, and at $24.74 per share, it is trading 65.6% below its 52-week high of $71.99 from September 2024. Investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at an investment worth $359.38.

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.